CompletedNot Applicable

Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients

Brazil27 participantsStarted 2012-07

Plain-language summary

Twenty-seven breast cancer women without heart failure, underwent CMR imaging (3T-Achieva, Philips) before and 3 times serially after 4-cycles of adjuvant DOX (60mg/m2). CMR assessed left ventricular (LV) ejection fraction (EF), T1 mapping pre and post gadolinium and late gadolinium enhancement imaging. Biomarkers were obtained before and 72 hours after each DOX-cycle.

Who can participate

Age range18 Years – 75 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Breast cancer and had prescribed an anthracycline agent as part of their chemotherapy regimen Exclusion Criteria: * Strict contraindications to MRI * Acute or chronic kidney failure * Previously diagnosed myocardial infarction, heart failure, valvular disease or cardiomyopathy.

What they're measuring

Quantification of fibrosis index by Cardiac Magnetic Resonance

Timeframe: two years

Intracellular lifetime of water (τic) by Cardiac Magnetic Resonance

Timeframe: two years

Trial details

NCT IDNCT03000036

SponsorUniversity of Campinas, Brazil

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-01

View on ClinicalTrials.gov More Breast Cancer Female trials